Overview

Mass Balance Study of [14C]Chiauranib

Status:
Not yet recruiting

Trial end date:
2023-06-30

Target enrollment:

Participant gender:

Summary

Chiauranib , which simultaneously targets against VEGFR/Aurora B/CSF-1R, several key kinases involved in tumor angiogenesis, tumor cell mitosis, and chronic inflammatory microenvironment.

Phase:

N/A

Details

Lead Sponsor:

Chipscreen Biosciences, Ltd.

Treatments:

Chiauranib